m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05351
 [1]
Non-coding RNA miR-135 ZNF217  lncRNA       miRNA   circRNA Indirect Enhancement m6A modification NANOG NANOG METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Homeobox protein NANOG (NANOG)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator MiR-135 family microRNA View Details
Regulated Target Zinc finger protein 217 (ZNF217) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary dual-luciferase reporter gene assay revealed the presence of direct binding between miR-135 and Zinc finger protein 217 (ZNF217). ZNF217 could upregulate Homeobox protein NANOG (NANOG) by reducing N6-methyladenosine levels via methyltransferase-like 13 (METTL3).
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Cell Process Cell migration
Cell invasion
Epithelial-mesenchymal transition initiation
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Zinc finger protein 217 (ZNF217) 8 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name ISIS 114563 Investigative [2]
External Link
TTD: D01KCM
 Compound Name ISIS 114559 Investigative [2]
External Link
TTD: D03NEA
 Compound Name ISIS 114531 Investigative [2]
External Link
TTD: D08WJY
 Compound Name ISIS 114527 Investigative [2]
External Link
TTD: D0AJ0H
 Compound Name ISIS 114537 Investigative [2]
External Link
TTD: D0E5FG
 Compound Name ISIS 14548 Investigative [2]
External Link
TTD: D0L3NU
 Compound Name ISIS 114532 Investigative [2]
External Link
TTD: D0LY0E
 Compound Name ISIS 114530 Investigative [2]
External Link
TTD: D0N5CF
2C60: Breast cancer 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Entrectinib Approved [3]
Synonyms
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
    Click to Show/Hide
External Link
CID: 25141092
TTD: D0O0LS
DrugBank: DB11986
 Compound Name Everolimus Approved [4]
External Link
CID: 6442177
TTD: D09ZSC
DrugBank: DB01590
References
Ref 1 MicroRNA-135 inhibits initiation of epithelial-mesenchymal transition in breast cancer by targeting ZNF217 and promoting m6A modification of NANOG. Oncogene. 2022 Mar;41(12):1742-1751. doi: 10.1038/s41388-022-02211-2. Epub 2022 Feb 4.
Ref 2 US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.
Ref 3 Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
Ref 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015